792 related articles for article (PubMed ID: 27367184)
1. The host STING pathway at the interface of cancer and immunity.
Corrales L; McWhirter SM; Dubensky TW; Gajewski TF
J Clin Invest; 2016 Jul; 126(7):2404-11. PubMed ID: 27367184
[TBL] [Abstract][Full Text] [Related]
2. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
Woo SR; Fuertes MB; Corrales L; Spranger S; Furdyna MJ; Leung MY; Duggan R; Wang Y; Barber GN; Fitzgerald KA; Alegre ML; Gajewski TF
Immunity; 2014 Nov; 41(5):830-42. PubMed ID: 25517615
[TBL] [Abstract][Full Text] [Related]
3. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
Deng L; Liang H; Xu M; Yang X; Burnette B; Arina A; Li XD; Mauceri H; Beckett M; Darga T; Huang X; Gajewski TF; Chen ZJ; Fu YX; Weichselbaum RR
Immunity; 2014 Nov; 41(5):843-52. PubMed ID: 25517616
[TBL] [Abstract][Full Text] [Related]
4. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
[TBL] [Abstract][Full Text] [Related]
5. STING pathway agonism as a cancer therapeutic.
Flood BA; Higgs EF; Li S; Luke JJ; Gajewski TF
Immunol Rev; 2019 Jul; 290(1):24-38. PubMed ID: 31355488
[TBL] [Abstract][Full Text] [Related]
6. Innate immune recognition of cancer.
Woo SR; Corrales L; Gajewski TF
Annu Rev Immunol; 2015; 33():445-74. PubMed ID: 25622193
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site.
Ohkuri T; Kosaka A; Ishibashi K; Kumai T; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Celis E; Kobayashi H
Cancer Immunol Immunother; 2017 Jun; 66(6):705-716. PubMed ID: 28243692
[TBL] [Abstract][Full Text] [Related]
8. New perspectives on type I IFNs in cancer.
Gajewski TF; Corrales L
Cytokine Growth Factor Rev; 2015 Apr; 26(2):175-8. PubMed ID: 25630967
[TBL] [Abstract][Full Text] [Related]
9. TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.
Francica BJ; Ghasemzadeh A; Desbien AL; Theodros D; Sivick KE; Reiner GL; Hix Glickman L; Marciscano AE; Sharabi AB; Leong ML; McWhirter SM; Dubensky TW; Pardoll DM; Drake CG
Cancer Immunol Res; 2018 Apr; 6(4):422-433. PubMed ID: 29472271
[TBL] [Abstract][Full Text] [Related]
10. Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy.
Iurescia S; Fioretti D; Rinaldi M
Recent Pat Anticancer Drug Discov; 2018; 13(1):2-17. PubMed ID: 29086701
[TBL] [Abstract][Full Text] [Related]
11. The STING pathway and the T cell-inflamed tumor microenvironment.
Woo SR; Corrales L; Gajewski TF
Trends Immunol; 2015 Apr; 36(4):250-6. PubMed ID: 25758021
[TBL] [Abstract][Full Text] [Related]
12. STING, DCs and the link between innate and adaptive tumor immunity.
Vatner RE; Janssen EM
Mol Immunol; 2019 Jun; 110():13-23. PubMed ID: 29273394
[TBL] [Abstract][Full Text] [Related]
13. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
Corrales L; Gajewski TF
Clin Cancer Res; 2015 Nov; 21(21):4774-9. PubMed ID: 26373573
[TBL] [Abstract][Full Text] [Related]
14. Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies.
Iurescia S; Fioretti D; Rinaldi M
Front Immunol; 2018; 9():711. PubMed ID: 29686682
[TBL] [Abstract][Full Text] [Related]
15. Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy.
Ager CR; Zhang H; Wei Z; Jones P; Curran MA; Di Francesco ME
Bioorg Med Chem Lett; 2019 Oct; 29(20):126640. PubMed ID: 31500996
[TBL] [Abstract][Full Text] [Related]
16. Novel chemical compound SINCRO with dual function in STING-type I interferon and tumor cell death pathways.
Kimura Y; Negishi H; Matsuda A; Endo N; Hangai S; Inoue A; Nishio J; Taniguchi T; Yanai H
Cancer Sci; 2018 Sep; 109(9):2687-2696. PubMed ID: 29981256
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity.
Burnette BC; Liang H; Lee Y; Chlewicki L; Khodarev NN; Weichselbaum RR; Fu YX; Auh SL
Cancer Res; 2011 Apr; 71(7):2488-96. PubMed ID: 21300764
[TBL] [Abstract][Full Text] [Related]
18. Activation of Stimulator of Interferon Genes (STING) and Sjögren Syndrome.
Papinska J; Bagavant H; Gmyrek GB; Sroka M; Tummala S; Fitzgerald KA; Deshmukh US
J Dent Res; 2018 Jul; 97(8):893-900. PubMed ID: 29505322
[TBL] [Abstract][Full Text] [Related]
19. Multi-Immune Agonist Nanoparticle Therapy Stimulates Type I Interferons to Activate Antigen-Presenting Cells and Induce Antigen-Specific Antitumor Immunity.
Levy ES; Chang R; Zamecnik CR; Dhariwala MO; Fong L; Desai TA
Mol Pharm; 2021 Mar; 18(3):1014-1025. PubMed ID: 33541072
[TBL] [Abstract][Full Text] [Related]
20. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
